
    
      This study will be a single center, randomized, open-label, 2-arm study to evaluate the
      effects of atorvastatin, a weak CYP3A4 inhibitor, on the PK of lomitapide in healthy male and
      female subjects when atorvastatin is administered simultaneously with lomitapide and when it
      is administered 12 hours after lomitapide.
    
  